J&J Tries To Ease EU Concerns Over $21B Synthes Deal
Johnson & Johnson has offered unnamed concessions meant to ease the European Commission's antitrust concerns over the company's proposed $21.3 billion acquisition of leading orthopedic device maker Synthes Inc., the regulator...To view the full article, register now.
Already a subscriber? Click here to view full article